osimertinib

Details

Files
Generic Name:
osimertinib
Project Status:
Complete
Therapeutic Area:
Non-small cell lung cancer
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Tagrisso
Project Line:
Reimbursement Review
Project Number:
PC0246-000
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openFebruary 24, 2021
Call for patient/clinician input closedApril 16, 2021
Clarification:

- Patient input submission received from Lung Cancer Canada, Canadian Cancer Survivor Network (CCSN), CanCertainty, and Lung Health Foundation/The Ontario Lung Association.

Submission receivedMarch 24, 2021
Submission accepted-
Review initiatedApril 09, 2021
Draft CADTH review report(s) provided to sponsor for commentJune 23, 2021
Deadline for sponsors commentsJuly 05, 2021
CADTH responses on draft review report(s) provided to sponsorJuly 29, 2021
Expert committee meeting (initial)August 11, 2021
Draft recommendation posted for stakeholder feedbackSeptember 02, 2021
End of feedback periodSeptember 17, 2021
Clarification:

- Reconsideration: minor revisions requested by sponsor

Final recommendation issued to sponsor and drug plansJanuary 10, 2022
Final recommendation postedJanuary 28, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)January 24, 2022
CADTH review report(s) postedMarch 04, 2022